Immuno-Oncology | Specialty

Dr. Atkins on Excitement With Atezolizumab and Bevacizumab in RCC

July 27th 2017

Michael B. Atkins, MD, deputy director, Georgetown-Lombardi Comprehensive Cancer Center, professor of oncology and medicine, Georgetown University School of Medicine, discusses the excitement surrounding the combination of atezolizumab (Tecentriq) plus bevacizumab (Avastin) in renal cell carcinoma (RCC).

Dr. Plimack on Combo of Pembrolizumab/Epacodostat in Bladder Cancer

July 27th 2017

Elizabeth Plimack, MD, director of Genitourinary Clinical Research at Fox Chase Cancer Center, discusses the phase Ib trial of epacodostat and pembrolizumab (Keytruda) in patients with urothelial carcinoma.

Diverse Approaches Needed to Further Advance Bladder Cancer Care

July 27th 2017

Elizabeth Plimack, MD, recaps recent advances in bladder cancer and discusses the need for diverse approaches to further improve patient outcomes.

Apolo Talks Progress, Future of Immunotherapy in Bladder Cancer

July 26th 2017

Andrea Apolo, MD, discusses a pooled analysis of the phase Ib Javelin Solid Tumor study, and a phase I study of cabozantinib, nivolumab, and ipilimumab.

FDA Accepts sBLAs for 4-week Nivolumab Dosing Schedule

July 26th 2017

The FDA has accepted supplemental Biologics License Applications seeking to add a second dosing schedule for nivolumab (Opdivo) across all of the PD-1 inhibitor’s monotherapy indications.

Dr. Choueiri on Synergy Between Immunotherapy and VEGF Inhibitors in RCC

July 26th 2017

Toni K. Choueiri, MD, director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, senior physician, Dana-Farber Cancer Institute, discusses the synergy between immunotherapy agents and VEGF inhibitors in renal cell carcinoma (RCC).

Dr. Garcia on Selecting Second-line Immunotherapy in Bladder Cancer

July 26th 2017

Jorge Garcia, MD, Department of Hematology and Oncology, Cleveland Clinic, discusses selecting a second-line and beyond immunotherapy treatment for patients with bladder cancer.

Rini Discusses Pembrolizumab/Axitinib, Other Emerging Combos in RCC

July 26th 2017

Brian Rini, MD, discusses the KEYNOTE-426 study and the promise of emerging combinations in renal cell carcinoma.

Dr. Bauml on Next Steps for Immunotherapy in Head and Neck Cancer

July 25th 2017

Joshua Bauml, MD, assistant professor, Perelman School of Medicine, University of Pennsylvania, discusses the next steps for immunotherapy in head and neck cancer.

Expert Discusses Pembrolizumab Plus Rituximab in Follicular Lymphoma

July 25th 2017

Loretta Nastoupil, MD, discusses the positive interim analysis and shared her thoughts on areas of future investigation for patients with relapsed follicular lymphoma.

FDA Approves Ipilimumab for Pediatric Melanoma

July 24th 2017

The FDA has approved ipilimumab for the treatment of patients aged ≥12 years with unresectable or metastatic melanoma.

Atezolizumab Approaches EU Approval for NSCLC, Urothelial Carcinoma

July 22nd 2017

The European Medicines Agency’s Committee for Medicinal Products for Human Use has taken a positive position on indications for atezolizumab in non-small cell lung cancer and urothelial carcinoma.

Dr. Balar on Combinations with Pembrolizumab for Urothelial Cancer

July 21st 2017

Arjun V. Balar, MD, assistant professor of Medicine, Division of Hematology and Oncology, New York University Cancer Institute, NYU Langone Medical Center, discusses combinations with pembrolizumab (Keytruda) for patients with urothelial carcinoma.

Dr. Sartor on Remaining Questions With Sipuleucel-T in mCRPC

July 21st 2017

Oliver Sartor, MD, a medical oncologist at the Tulane University School of Medicine, discusses the remaining questions with sipuleucel-T (Provenge) in metastatic castration-resistant prostate cancer.

Avelumab Recommended for EU Approval for Merkel Cell Carcinoma

July 21st 2017

The European Medicines Agency's Committee for Medicinal Products for Human Use has recommended approval of avelumab (Bavencio) for adults with metastatic Merkel cell carcinoma, according to Pfizer and Merck, the codevelopers of the PD-L1 inhibitor.

Expert Discusses Key Immunotherapy Trials and Next Steps in Head and Neck Cancer

July 21st 2017

Joshua Bauml, MD, discusses the current role of immunotherapy in this disease, potential next steps, and unmet needs in HPV-associated head and neck cancer.

Dr. Burtness on Combinations of Immunotherapy in Head and Neck Cancer

July 21st 2017

Barbara Burtness, MD, professor of Medicine, Yale Cancer Center, discusses immunotherapy combinations for patients with head and neck cancer.

Dr. Rini on Sequencing of Immunotherapy Combinations in RCC

July 21st 2017

Brian I. Rini, MD, professor of Medicine, Cleveland Clinic, discusses sequencing of immunotherapy combinations for patients with renal cell carcinoma (RCC).

Nivolumab/Ipilimumab Combo Shows Durable Activity in Small Cell Lung Cancer

July 20th 2017

Mathew D. Hellmann, MD, discusses the first report of the randomized expansion cohort from CheckMate-032 in small cell lung cancer.

NEJM Data Detail Nivolumab Findings in Frontline NSCLC

July 20th 2017

Results now published in the New England Journal of Medicine show that nivolumab (Opdivo) was not superior for progression-free survival compared with chemotherapy as a first-line treatment for patients with NSCLC.